Table 1.

Multivariable Cox regression of baseline uric acid as a continuous variable to outcome in the placebo and empagliflozin groups

	Placebo			Empagliflozin
	Patients with event, n	HR (95% CI) for outcomes by increase of 1 unit in baseline uric acid (mg/dL = 59.48 μmol/L)	P	Patients with event, n	HR (95% CI) for outcomes by increase of 1 unit in baseline uric acid (mg/dL = 59.48 μmol/L)	P
Three‐point MACE	282	1.06 (0.98–1.15)	0.1406	490	1.15 (1.09–1.22)	<0.0001
CV death	137	1.09 (0.98–1.22)	0.1039	172	1.18 (1.08–1.30)	0.0005
HHF	94	1.25 (1.10–1.41)	0.0006	126	1.21 (1.10–1.34)	0.0002
HHF or CV death	197	1.14 (1.04–1.24)	0.0053	265	1.19 (1.11–1.28)	<0.0001
ACM	194	1.07 (0.98–1.17)	0.1528	269	1.18 (1.09–1.27)	<0.0001
Incident or worsening nephropathy	387	1.17 (1.09–1.25)	<0.0001	525	1.14 (1.08–1.21)	<0.0001

Abbreviations: ACM, all‐cause mortality; BMI, body mass index; CV, cardiovascular; HF, heart failure; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular events.

Cox model included age, sex, baseline BMI (categorical), baseline HbA1c (categorical), baseline eGFR (categorical), region, baseline uric acid (continuous), use of baseline diuretics, baseline anti‐gout medication and baseline HF. The composite endpoint of HHF or CV death excludes fatal stroke.